Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73319 | 0.80 | CA12 (0.44) | CA12CA2CA9MEN1HTT | |
| SCHEMBL11044440 | 0.78 | CA12 (0.50) | CA12CA2CA9MEN1HTT | |
| SCHEMBL2201285 | 0.78 | CA12 (0.50) | CA12CA2CA9MEN1HTT | |
| SCHEMBL5536973 | 0.77 | CA12 (0.41) | CA12CA2CA9MEN1HTT | |
| SCHEMBL8529536 | 0.76 | CA12 (0.48) | CA12CA2CA9MEN1HTT | |
| SCHEMBL21534 | 0.76 | CA12 (0.48) | CA12CA2CA9MEN1HTT | |
| SCHEMBL5541825 | 0.75 | APP (0.43) | HTTTAAR1TSHRALDH1A1 | |
| SCHEMBL2091801 | 0.75 | CHKA (0.43) | CHKAALDH1A1 | |
| SCHEMBL2103019 | 0.75 | CHRM5 (0.54) | MEN1KMT2ACHKA | |
| SCHEMBL5541551 | 0.75 | SIGMAR1 (0.41) | CA12CA2CA9TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113816934-B | Synthesis method of disubstituted chromanone and application of disubstituted chromanone in treatment of pulmonary inflammation such as COPD (chronic infectious disease) | 广东省科学院动物研究所 | 2023-08-01 | — | — | CN | claimed |
| WO-2023045302-A1 | METHOD FOR SYNTHESIZING DISUBSTITUTED BENZODIHYDROPYRONE COMPOUND AND USE THEREOF IN TREATMENT OF PULMONARY INFLAMMATIONS SUCH AS COPD | 广东省科学院动物研究所 | 2023-03-30 | — | — | WO | claimed |
| CN-113045527-B | Dihydrothromone derivative and synthesis method and application thereof | 广东省科学院动物研究所 | 2022-11-08 | — | — | CN | claimed |
| CN-113816934-A | Synthesis method of disubstituted chromanone and application of disubstituted chromanone in treating pulmonary inflammation such as COPD (chronic obstructive pulmonary disease) | 广东省科学院动物研究所 | 2021-12-21 | — | — | CN | claimed |
| CN-113045527-A | Dihydrothromone derivative and synthesis method and application thereof | 广东省科学院动物研究所 | 2021-06-29 | — | — | CN | claimed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | claimed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| CN-101410366-A | Substituted bicyclic ring derivatives and uses thereof | ASAHI KASEI PHARMA CORP (JP) | 2009-04-15 | — | — | CN | claimed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | claimed |
| EP-0400660-A1 | 1,4-dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1990-12-05 | — | — | EP | claimed |
| US-4958024-A | REACTION OF CARBAMATE SUBSTITUTED ACRYLIC ESTER, VASODILATORS, HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-09-18 | — | — | US | claimed |
| US-4914227-A | FOR VASODILATING AND HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-04-03 | — | — | US | claimed |
| EP-0320984-A2 | 1,4-Dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1989-06-21 | — | — | EP | claimed |
| EP-0131374-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PENEM DERIVATIVES | PFIZER INC. (US) | 1988-11-23 | — | — | EP | claimed |
| US-4739106-A | VASODILATION, HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1988-04-19 | — | — | US | claimed |
| EP-0101023-B1 | PROCESS FOR PREPARING 2-CARBAMOYLOXYALKYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND INTERMEDIATES USEFUL FOR THE PROCESS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-07-29 | — | — | EP | claimed |
| US-4619783-A | BACTERICIDES | PFIZER INC. (US) | 1986-10-28 | — | — | US | claimed |
| EP-0131374-A1 | Process and intermediates for the preparation of penem derivatives | PFIZER INC. (US) | 1985-01-16 | — | — | EP | claimed |
| EP-0063359-A1 | 1,4-Dihydropyridine derivatives and processes for preparing the same | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1982-10-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | CA12 3810/4885CA2 1002/4885CA9 1576/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | CA12 3810/4885CA2 1002/4885CA9 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.